{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:50:58Z","timestamp":1781736658787,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.gore.2023.101251","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T21:35:23Z","timestamp":1691012123000},"page":"101251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making"],"prefix":"10.1016","volume":"49","author":[{"given":"Evi","family":"Abada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaljeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ruhul","family":"Quddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9742","key":"10.1016\/j.gore.2023.101251_b0005","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A Phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gore.2023.101251_b0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/10668969221102529","article-title":"The prognostic effect of HER2 gene amplification in high-grade endometrial carcinomas and its correlation with protein overexpression","volume":"31","author":"Bozkurt","year":"2023","journal-title":"International Journal of Surgical Pathology"},{"key":"10.1016\/j.gore.2023.101251_b0015","doi-asserted-by":"crossref","unstructured":"Buza, N. (2021). HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. Int J Gynecol Pathol, 40(1), 17-23.https:\/\/doi.org\/10.1097\/PGP.0000000000000711.","DOI":"10.1097\/PGP.0000000000000711"},{"key":"10.1016\/j.gore.2023.101251_b0020","doi-asserted-by":"crossref","unstructured":"de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial [published correction appears in Lancet Oncol. 2018 Apr;19(4):e184].Lancet Oncol. 2018;19(3):295-309. doi:10.1016\/S1470-2045(18)30079-2.","DOI":"10.1016\/S1470-2045(18)30079-2"},{"issue":"2","key":"10.1016\/j.gore.2023.101251_b0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","article-title":"HER2 expression beyond breast cancer: Therapeutic implications for gynecologic malignancies","volume":"17","author":"English","year":"2013","journal-title":"Molecular Diagnosis & Therapy"},{"issue":"15","key":"10.1016\/j.gore.2023.101251_b0030","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): Updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10.1016\/j.gore.2023.101251_b0035","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/ijgc-2021-002753","article-title":"Uterine serous carcinoma: Key advances and novel treatment approaches","volume":"31","author":"Ferriss","year":"2021","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1016\/j.gore.2023.101251_b0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"Gynecologic oncology group an exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1016\/j.gore.2023.101251_b0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/PGP.0b013e31823bb24d","article-title":"HER2\/neu as a potential target for immunotherapy in gynecologic carcinosarcomas","volume":"31","author":"Guzzo","year":"2012","journal-title":"International Journal of Gynecological Pathology"},{"issue":"2","key":"10.1016\/j.gore.2023.101251_b0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14216\/kjco.20011","article-title":"Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy","volume":"16","author":"Ha","year":"2020","journal-title":"Korean J Clin Oncol."},{"issue":"4","key":"10.1016\/j.gore.2023.101251_b0055","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","article-title":"HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology","volume":"46","author":"Jenkins","year":"2022","journal-title":"The American Journal of Surgical Pathology"},{"key":"10.1016\/j.gore.2023.101251_b0060","doi-asserted-by":"crossref","unstructured":"A.S. Joehlin-Price M.K. Komforti N.R. Ladwig et al. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy [published online ahead of print, 2023 Mar 20] Am J Surg Pathol. 2023; 10.1097\/PAS.0000000000002030. 10.1097\/PAS.0000000000002030.","DOI":"10.1097\/PAS.0000000000002030"},{"issue":"9","key":"10.1016\/j.gore.2023.101251_b0065","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00262-010-0869-2","article-title":"Anti-HER2 vaccines: New prospects for breast cancer therapy","volume":"59","author":"Ladjemi","year":"2010","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"11","key":"10.1016\/j.gore.2023.101251_b0070","doi-asserted-by":"crossref","first-page":"e49829","DOI":"10.1371\/journal.pone.0049829","article-title":"Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels","volume":"7","author":"Lanitis","year":"2012","journal-title":"PLoS One1"},{"issue":"1","key":"10.1016\/j.gore.2023.101251_b0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","article-title":"EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma","volume":"100","author":"Livasy","year":"2006","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/j.gore.2023.101251_b0080","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13058-015-0648-2","article-title":"The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer\u2013a systematic review","volume":"17","author":"Mendes","year":"2015","journal-title":"Breast Cancer Research"},{"issue":"1","key":"10.1016\/j.gore.2023.101251_b0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.gore.2023.101251_b0090","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: Association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.gore.2023.101251_b0095","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3816\/CBC.2008.n.047","article-title":"Unraveling the biologic and clinical complexities of HER2","volume":"8","author":"Park","year":"2008","journal-title":"Clinical Breast Cancer"},{"issue":"4","key":"10.1016\/j.gore.2023.101251_b0100","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajog.2005.12.020","article-title":"Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed m\u00fcllerian tumors","volume":"194","author":"Rice","year":"2006","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"4","key":"10.1016\/j.gore.2023.101251_b0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1634\/theoncologist.3-4-237","article-title":"The HER-2\/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy","volume":"3","author":"Ross","year":"1998","journal-title":"The Oncologist"},{"issue":"7","key":"10.1016\/j.gore.2023.101251_b0110","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/cncr.21308","article-title":"Amplification of c-erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma","volume":"104","author":"Santin","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.gore.2023.101251_b0115","doi-asserted-by":"crossref","first-page":"R256","DOI":"10.1186\/bcr991","article-title":"Long-term prognostic significance of HER-2\/neu in untreated node-negative breast cancer depends on the method of testing","volume":"7","author":"Schmidt","year":"2005","journal-title":"Breast Cancer Research"},{"issue":"5 Suppl 16","key":"10.1016\/j.gore.2023.101251_b0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0093-7754(01)90284-2","article-title":"Anticancer therapy targeting the erbB family of receptor tyrosine kinases","volume":"28","author":"Slichenmyer","year":"2001","journal-title":"Seminars in Oncology"},{"issue":"3","key":"10.1016\/j.gore.2023.101251_b0125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of HER2 in cancer therapy and targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"Journal of Controlled Release"},{"issue":"4","key":"10.1016\/j.gore.2023.101251_b0130","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/ijgc-2020-001822","article-title":"Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy","volume":"31","author":"van den Heerik","year":"2021","journal-title":"International Journal of Gynecological Cancer"},{"issue":"20","key":"10.1016\/j.gore.2023.101251_b0135","first-page":"2105","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of american pathologists clinical practice guideline focused update [published online june 7, 2023]","volume":"36","author":"Wolff","year":"2023","journal-title":"Arch Pathol and Lab Med"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923001200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923001200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:59:09Z","timestamp":1762480749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923001200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":27,"alternative-id":["S2352578923001200"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101251","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101251"}}